This market research report estimates that the global pancreatic cancer drug market will be worth USD 1.2 billion by 2015. The report provides analysis and forecasts for the pancreatic cancer market from 2012-2018. Pancreatic cancer is caused by the unrestrained growth of cells in the pancreas. This abnormal, uncontrolled growth of cells leads to the formation of lumps of tissue, commonly referred to as tumors. The presence of tumors hinders the normal functioning of pancreas.
Pancreatic cancer is a key challenge in the United States, where the 30,000 patients are diagnosed with the disease each year. The U.S. has the highest number of pancreatic cancer patients in the world. With less than five-year survival, the pancreatic cancer market has among the highest unmet therapy needs in the overall oncology market. Evidently, this is also the greatest challenge that the pancreatic cancer market needs to address. Given the aggressive nature of pancreatic cancer, treatments often return inadequate results. This aspect is yet another barrier to the growth of this market.
Technologies for the timely diagnosis of this cancer type are yet to develop fully, which results in a majority of pancreatic cancer patients being diagnosed at an advanced stage of the disease. This reflects in the high mortality rates associated with pancreatic cancer. Estimates show that only a small percentage (about 12% to 15%) of patients is diagnosed early enough to be treated with surgical procedures, drugs, and chemotherapy. Pancreatic cancer begins at stage I, with the subsequent stages being: stage II, stage III, and stage IV. Only stage I and stage II pancreatic cancers can be surgically removed.
The pancreatic cancer market is segmented based on whether the cancer affects endocrine or exocrine functions. Adenocarcinomas, which constitutes nearly 95% of all exocrine pancreatic cancers, is the most common pancreatic cancer type. Other prevalent cancers of the pancreas that affect endocrine functions include: squamous cell carcinomas, adenosquamous carcinomas, and giant cell carcinomas.
The pancreatic cancer drug market is dominated by Gemzar (Gemcitabine) developed by Eli Lilly. Gemzar is ranks among the most advanced types of drug therapies recommended advanced stage treatments (stage III and stage IV). A majority of the pancreatic cancer drug market is led by Gemzar developed by Eli Lilly and Tarceva(Erlotinib), by Genentech/ OSI Pharmaceuticals/ Roche as they have been in the market for a considerable time. At the beginning of the decade, Gemzar hold sway over 55% of the overall pancreatic cancer market.
Abraxane by Celgene, is another therapeutic drug that was launched in the US in 2013, and in Europe in 2014. Abraxane was the first drug to be approved for pancreatic cancer treatment in almost a decade, and is expected to aggressively compete with existing drugs. A few pipeline drugs are expected to be launched toward the end of the forecast period. Numerous untapped opportunities in clinical development exist in the pancreatic cancer market.
This report marks out unmet needs and opportunities in the current pancreatic treatment landscape. It also offers intelligence pertaining to pipeline drugs and commercial prospects in the global pancreatic cancer market. It focuses on early-stage and advanced-stage market alike. The report analyzes and forecasts the market from 2012 through 2018, providing details about market growth drivers, barriers, and trends. The study also features leading market players and documents their growth strategy in the Company Profiles section.
Geographies analyzed under this research report:
- North America
- Rest of the World
This report gives you access to decisive data such as:
- Market growth drivers
- Factors limiting market growth
- Current market trends
- Market structure
- Market projections for the coming years
Key highlights of this report:
- Overview of key market forces propelling and restraining market growth
- Up-to-date analyses of market trends and technological improvements in the micro servers industry
- Pin-point analyses of market competition dynamics to offer you a competitive edge
- An analysis of strategies of major competitors
- An array of graphics and SWOT analysis of major industry segments
- Detailed analyses of industry trends
- A well-defined technological growth map with an impact-analysis
- Offers a clear understanding of the competitive landscape and key product segments